Want to see SG:BXE full AI Analyst Report?
Top Page
CDW Holding
(SGX:BXE)
Select Model
Select Model
Rating:44Neutral
Price Target:
S$0.07
▼(-47.69% Downside)
Action:Reiterated
Date:09/06/26
The score is held down primarily by deteriorating financial performance (multi-year losses, TTM revenue decline, and recent negative operating/free cash flow). Technicals reinforce the weakness with price below all key moving averages and negative MACD. Valuation gets modest support from the very high dividend yield, but the negative P/E and loss-making profile cap the benefit.
Positive Factors
Modest Leverage
Modest leverage gives CDW Holding some balance-sheet flexibility and limits the immediate burden of debt service. This can preserve room for operations and investment, although that cushion could weaken if losses and cash consumption continue over subsequent quarters.
Negative Factors
Revenue and Profitability Decline
The combination of sharp revenue contraction and continuing EBIT and net losses signals weakening demand or operating economics. Repeated losses reduce earnings resilience, constrain internal funding, and make a durable recovery dependent on reversing the underlying revenue and cost pressures.
Read all positive and negative factors
Positive Factors
Negative Factors
Modest Leverage
Modest leverage gives CDW Holding some balance-sheet flexibility and limits the immediate burden of debt service. This can preserve room for operations and investment, although that cushion could weaken if losses and cash consumption continue over subsequent quarters.
Read all positive factors
CDW Holding (BXE) vs. iShares MSCI Singapore ETF (EWS)
Market Cap
S$15.54M
Dividend Yield14.7%
Average Volume (3M)54.19K
Price to Earnings (P/E)―
Beta (1Y)0.54
Revenue Growth-17.70%
EPS Growth-58.79%
CountrySG
Employees414
SectorTechnology
Sector Strength88
IndustryHardware, Equipment & Parts
Share Statistics
EPS (TTM)-0.02
Shares Outstanding252,177,110
10 Day Avg. Volume63,240
30 Day Avg. Volume54,190
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)0.58
Price to Sales (P/S)0.26
P/FCF Ratio15.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
CDW Holding Business Overview & Revenue Model
Company Description
Established in 1991 and headquartered in Sha Tin, Hong Kong, CDW Holding Limited functions as an investment holding company with a global reach, including significant operations in Mainland China and Japan. The company primarily manufactures and d...
How the Company Makes Money
null...
CDW Holding Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
62
Positive
Cash Flow
36
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 72.32M | 88.72M | 85.80M | 109.22M | 147.99M | 143.24M |
| Gross Profit | 10.48M | 12.31M | 13.55M | 18.72M | 25.68M | 26.11M |
| EBITDA | -4.44M | ― | -1.53M | 2.57M | 19.74M | 7.50M |
| Net Income | -5.08M | -2.67M | -4.42M | -1.07M | 14.41M | 2.35M |
Balance Sheet | ||||||
| Total Assets | 59.42M | 68.16M | 115.04M | 95.97M | 117.54M | 108.82M |
| Cash, Cash Equivalents and Short-Term Investments | 20.34M | 24.89M | 26.55M | 27.40M | 27.26M | 28.60M |
| Total Debt | 8.14M | 7.56M | 8.36M | 9.84M | 16.23M | 13.48M |
| Total Liabilities | 24.80M | 29.83M | 40.67M | 42.55M | 58.94M | 58.12M |
| Stockholders Equity | 36.24M | 39.89M | 44.90M | 54.66M | 59.50M | 50.69M |
Cash Flow | ||||||
| Free Cash Flow | -5.24M | 1.46M | 4.71M | 9.54M | 4.10M | 2.50M |
| Operating Cash Flow | -3.70M | 2.48M | 5.34M | 10.95M | 4.96M | 3.78M |
| Investing Cash Flow | -698.00K | -2.76M | -433.00K | 526.00K | -1.16M | -2.60M |
| Financing Cash Flow | -1.46M | -4.07M | -5.54M | -10.54M | -1.42M | -6.93M |
CDW Holding Technical Analysis
Negative
0.13
Price Trends
0.08
Negative
0.08
Negative
0.10
Negative
Market Momentum
>-0.01
Positive
38.65
Neutral
25.93
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:BXE, the sentiment is Negative. The current price of 0.13 is above the 20-day moving average (MA) of 0.08, above the 50-day MA of 0.08, and above the 200-day MA of 0.10, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 38.65 is Neutral, neither overbought nor oversold. The STOCH value of 25.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SG:BXE.
CDW Holding Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | S$367.04M | 23.08 | 29.56% | 2.27% | 15.82% | 28.36% | |
74 Outperform | S$2.25B | 38.90 | 12.58% | 1.81% | 9.88% | 33.33% | |
68 Neutral | S$427.60M | 21.20 | 7.94% | 6.23% | -7.63% | -33.33% | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
57 Neutral | S$2.78B | 61.27 | 8.82% | 0.43% | 14.91% | 226.44% | |
44 Neutral | S$15.54M | -2.45 | -13.34% | 14.70% | -17.70% | -58.79% |
* Technology Sector Average
SG:BXE
CDW Holding
0.07
-0.06
-47.37%
SG:5DD
Micro-Mechanics (Holdings)
2.64
0.90
52.07%
SG:558
UMS Integration
2.54
1.48
139.85%
SG:BN2
Valuetronics Holdings
0.99
0.24
32.00%
SG:AWX
AEM Holdings Ltd.
8.70
7.16
463.84%
SG:BDR
Willas-Array Electronics (Holdings) Limited
1.11
0.03
2.78%
CDW Holding Corporate Events
CDW Holding Names New Legal Representative for Thai Subsidiary
Aug 28, 2026
CDW Holding Limited has appointed Mr. Chan Kam Wah as the sole director and legal representative of its Thai subsidiary, Tomoike Precision Machinery (Thailand) Co., Ltd., with immediate effect. The move strengthens governance and oversight of the ...
CDW’s LNP-LANFA Drug Delivery Platform Posts Promising Preclinical Results
Jun 29, 2026
CDW Holding’s biotech subsidiary ABio, together with Neoregen Biotech, has reported strong preclinical results in mice for LNP-LANFA, a next-generation lipid nanoparticle platform designed to deliver nucleic acid therapeutics and mRNA vaccin...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.